GlycoNano™ Tissue-specific Bioink Production Service
Overview of Bioink in 3D Bioprinting
Biofabrication encompasses the automated production of structurally organized, biologically functional products through the integration of bioactive molecules, living cells, and cell aggregates—including micro-tissues, biomaterials, or hybrid constructs of cells and materials—via processes such as bioassembly or bioprinting, culminating in subsequent tissue maturation. The emergence of 3D bioprinting as a novel biofabrication approach has been particularly noteworthy, offering enhanced control over the architectural organization of printed tissue constructs, a feature largely attributable to the automated deposition process, which confers high reproducibility. Across the bioprinting strategy, the bioink remains a critical component, requiring stabilization or cross-linking during or immediately post-printing to achieve the desired tissue construct shapes. Therefore, CD BioGlyco provides an advanced Platform for offering the Bioink Production Service where the choice of bioink depends on the intended application, such as target tissue.
Precision Printing, Tissue-Specific, Boundless Innovation
The process of our GlycoNano™ tissue-specific bioink production service is meticulously designed to tailor bioinks to the specific requirements of the target tissue. Here's a detailed description of the process:
3D Structure Design and Construction
Computer-aided design (CAD) and computer-aided manufacturing (CAM) tools are employed to construct the corresponding 3D structure of the scaffold. These technologies allow for precise customization of the scaffold to match the specific tissue geometry.
Bioink Formulation
The composition of the bioink is carefully formulated, taking into account the desired characteristics specified in the property requirements of bioinks/scaffolds. Common materials we use include chitosan, alginate, carrageenan, and so on. Cells encapsulated within the bioink can be derived from autologous or allogeneic sources, ensuring that the bioink is both biocompatible and capable of promoting cell growth and differentiation.
Quality Control and Testing
Each batch of bioink undergoes rigorous quality control to ensure it meets the required biocompatibility, mechanical properties, and cell viability. The bioink is tested in vitro to assess its performance in supporting cell growth and differentiation, as well as its compatibility with the intended tissue type.
GlycoNano™ Skin Bioink Production Service
In CD BioGlyco, we design various bioink formulas to produce highly specialized bioinks tailored for specific tissue engineering applications. These bioinks are formulated to mimic the unique structural and functional characteristics of various human tissues, making them essential for 3D bioprinting in regenerative medicine and tissue engineering.
GlycoNano™ Bone Bioink Production Service
Our bioinks are specifically designed to mimic the unique mineralized structure and properties of natural bone tissue. They effectively promote bone cell differentiation and mineralization, making them ideal for applications in bone defect repair, orthopedic research, and testing the biocompatibility of implants. Through our innovative approach, we aim to enhance treatments and outcomes in the field of bone regeneration and repair.
GlycoNano™ Cardio Bioink Production Service
We offer a specialized cardio bioink production Service for cardiovascular tissue engineering. Our bioinks are designed to mimic the mechanical properties and microarchitecture of cardiac tissue, incorporating cardiomyocyte-supportive ECM components and cardiac-specific growth factors. These features facilitate the generation of functional cardiac tissue models, making them ideal for studying heart disease progression, drug toxicity screening, and developing cardiac repair strategies.
GlycoNano™ Hepar Bioink Production Service
We specialize in producing hepar bioinks for liver tissue engineering applications, supporting hepatocyte function, including metabolic processes and drug detoxification, making them ideal for modeling liver diseases, studying drug metabolism, and exploring liver regeneration strategies. Through our commitment to innovation and quality, we strive to advance the field of liver regenerative medicine and improve treatments for liver-related conditions.
Workflow

Publication Data
DOI: 10.18063/IJB.2016.01.009
Journal: International Journal of Bioprinting
Published: 2016
IF: .6.8
Result: In this study, authors optimized polyelectrolyte gelatin-chitosan hydrogels for 3D bioprinting by addressing the poor printability and long crosslinking times of collagen-based materials. Chitosan, known for its antimicrobial and hemostatic properties, is modified by combining it with oppositely charged functional groups from gelatin at a pH of 6.5 to form polyelectrolyte complexes. The hydrogels were evaluated for physical interactions, rheological properties, printing resolution, and biocompatibility with fibroblast skin cells. The results show that the optimized hydrogels are suitable for 3D bioprinting at room temperature, achieving high shape fidelity and good biocompatibility, making them promising for wound healing and tissue engineering applications.
Applications
- By mimicking the structure and function of natural skin, it supports faster and more effective wound healing.
- Our bioinks can be used to create bone-like scaffolds that are crucial for testing orthopedic implants and studying bone biology.
- Our bioinks can be used to study that how drugs are metabolized in the liver, identifying potential side effects and improving drug design.
Advantages
- Our production service includes 3D structure design, bioink formulation, and rigorous quality control and testing to ensure optimal performance.
- We utilize advanced materials such as chitosan, alginate, and carrageenan, combined with cutting-edge CAD/CAM technologies for precise scaffold customization.
- Our services are adaptable to a wide range of tissue types, including skin, bone, cardiac, and liver, catering to diverse research and medical needs.
Frequently Asked Questions
- What types of material bioinks do we have?
- Chitosan-based material bioink
- Alginate-based material bioink
- Carrageenan-based material bioink
- Gellan gum-based material bioink
- Methacrylated alginate-based material bioink
- Methacrylated hyaluronic acid-based material bioink
- Thiolated-hyaluronic acid-based material bioink
- Thiolated-hyaluronic acid & gelatin-based material bioink
- Thiolated-hyaluronic acid & heparin-based material bioink
- Methacrylated dextran-based material bioink
- Methacrylated chitosan-based material bioink
- Alginate & cellulose-based material bioink
- Nanofibrillar cellulose-based material bioink
- Alginate & nanofibrillated cellulose-based material bioink
- Alginate & gelatin methacryloyl-based material bioink
- Alginate & collagen-based material bioink
- Alginate & mColMA-based material bioink
- Alginate & mColSA-based material bioink
- What else can glyconanomaterials be used for besides configuring bioinks?
Glyconanomaterials can be utilized in the development of various sensors, including:- Glucose Sensor Development Service: Creating advanced sensors for monitoring glucose levels, which is crucial for managing diabetes and other metabolic disorders.
- Pathogenic Bacteria and Toxin Sensor Development Service: Developing sensors to detect harmful bacteria and toxins, enhancing food safety, water quality monitoring, and public health surveillance.
- Cytosensor Development Service: Designing sensors that interact with cells to monitor cellular activities, which is invaluable in biomedical research and drug development.
- Lectin Sensor Development Service: Utilizing lectins in sensors to detect specific sugars or glycoconjugates, which can be applied in diagnostics and biomolecule detection.
At CD BioGlyco, through a comprehensive process, we ensure the production of high-quality, customized bioinks that are perfectly suited for the regeneration of various tissues. Whether you require bioinks for skin, bone, cardiovascular, or liver tissue engineering, contact us to obtain tailored solutions that accelerate your research and bring you closer to achieving successful tissue regeneration.
Reference
- Ng, W.L., et al. Polyelectrolyte gelatin-chitosan hydrogel optimized for 3D bioprinting in skin tissue engineering. International Journal of Bioprinting. 2016, 2(1): 53-62.
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform





